Favorable outcome of retreatment by direct-acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure.
Hiroki TojimaSatoru KakizakiSatoshi TakakusagiTakashi HoshinoAtsushi NaganumaTamon NagashimaMasashi NamikawaTakashi UenoYasushi ShimadaTakeshi HatanakaDaichi TakizawaHirotaka AraiKen SatoHitoshi TakagiToshio UraokaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2019)
Amino acid substitutions were frequently observed in patients with DCV + ASV failure, but most patients achieved a sustained virological response after retreatment with DAAs. Although the spread of drug-resistant viruses due to unsuccessful DAA treatment was a matter of concern, most cases of DCV + ASV failure were overcome with additional treatment.
Keyphrases
- combination therapy
- drug resistant
- hepatitis c virus
- multidrug resistant
- end stage renal disease
- acinetobacter baumannii
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- hiv infected
- peritoneal dialysis
- pseudomonas aeruginosa
- hiv infected patients
- antiretroviral therapy
- replacement therapy
- patient reported